Biotech CEOs discuss the importance of culture, getting through challenging times, their policy wishlist, and how they are proud of the ways our industry gives back
From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers
From London: Edward Hodgkin is the Executive Chair of Syncona's 'Slingshot', a platform that takes early stage science from academic labs that isn't ready to be a company and helps matures it
From London: Purespring Therapeutics is developing a gene therapy that is delivered locally to the podocytes in the kidney and aims to treat IgAN as its initial indication
From London: Resolution Therapeutics is in the clinic with its engineered regenerative macrophage therapy to treat end stage liver disease
BiotechTV - News
France